Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Syndax Pharmaceuticals (SNDX) Assets Average (2016 - 2025)

Syndax Pharmaceuticals has reported Assets Average over the past 10 years, most recently at $540.7 million for Q4 2025.

  • Quarterly results put Assets Average at $540.7 million for Q4 2025, down 6.01% from a year ago — trailing twelve months through Dec 2025 was $540.7 million (down 6.01% YoY), and the annual figure for FY2025 was $627.3 million, down 6.22%.
  • Assets Average for Q4 2025 was $540.7 million at Syndax Pharmaceuticals, down from $574.0 million in the prior quarter.
  • Over the last five years, Assets Average for SNDX hit a ceiling of $682.8 million in Q1 2025 and a floor of $251.3 million in Q3 2021.
  • Median Assets Average over the past 5 years was $448.5 million (2023), compared with a mean of $459.8 million.
  • Biggest five-year swings in Assets Average: skyrocketed 244.02% in 2021 and later fell 6.01% in 2025.
  • Syndax Pharmaceuticals' Assets Average stood at $344.6 million in 2021, then grew by 24.34% to $428.5 million in 2022, then grew by 18.11% to $506.1 million in 2023, then grew by 13.69% to $575.3 million in 2024, then fell by 6.01% to $540.7 million in 2025.
  • The last three reported values for Assets Average were $540.7 million (Q4 2025), $574.0 million (Q3 2025), and $618.4 million (Q2 2025) per Business Quant data.